Bringing the power of data and artificial intelligence to healthcare.
the discovery of novel targets
the effectiveness of treatments
potentially life-saving clinical trials
multiple diseases earlier
We can assist pharmaceutical and biotech companies with better drug development.
Learn MoreWe have built a proprietary Platform to make data accessible and deploy AI at scale.
Learn MoreThrough our scientific publications and research projects, we are accelerating and transforming personalized patient care.
View All Publications
Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities
Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.
A Pan-cancer Organoid Platform for Precision Medicine
Showcasing a robust pan-cancer tumor organoid (TO) platform, revealing genomic/transcriptome fidelity of TO culture from >1,000 patients. We demonstrate a neural-network-based high-throughput approach for label-free, light-microscopy-based drug assays capable of predicting patient-specific heterogeneity in drug responses with applicability across solid cancers.
Validation of a Liquid Biopsy Assay with Molecular and Clinical Profiling of Circulating Tumor DNA
Actionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.
The U.S. Food & Drug Administration (FDA) granted Tempus Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test.
READ PRESS RELEASETempus introduced its standalone RNA next-generation sequencing assay, Tempus xR. xR is a whole transcriptome panel for solid tumors, reporting clinically relevant fusions for more than 100 targeted genes, as well as altered splicing for MET Exon 14 and EGFRvIII.
READ PRESS RELEASETempus announced the broad launch of Tempus One – the first, AI-enabled clinical assistant that leverages advancements in generative AI to provide clinicians access to patient insights directly at their fingertips.
READ PRESS RELEASEThis is the future of healthcare.
